The Medical Letter on Drugs and Therapeutics
Issue 1316
Acetaminophen Safety - Deja Vu; Golimumab (Simponi) for Inflammatory Arthritis
The full issue is available to subscribers Subscriber Login   
Acetaminophen Safety - Deja Vu

Concerns have surfaced again at the FDA and in the media about the safety of acetaminophen and the multiplicity of products on the market in the US that contain various amounts of it. The text below is reprinted verbatim from The Medical Letter 2002; 44:91. The table that follows on the next page is current.

Acetaminophen Safety [2002]

An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen.1

ANALGESIC EFFECTIVENESS — Mild to moderate pain often responds to two regular strength 325-mg tablets of acetaminophen. A recent meta-analysis found that 1000 mg of acetaminophen (2 extra-strength 500-mg tablets) was somewhat more effective than 600-650 mg in treating moderate to severe postoperative pain, mainly after oral, gynecologic or orthopedic surgery.2 There are ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1316
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35